|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 12,280,151
What is U.S. Patent 12,280,151?
U.S. Patent 12,280,151, granted on March 21, 2023, to GlaxoSmithKline (GSK), covers a novel class of pharmaceutical compounds designed for use in treating respiratory diseases. The patent claims focus on a specific family of compounds characterized by unique chemical structures and their use in medicaments.
What is the detailed scope of the patent?
The scope is centered on:
- Chemical compounds: Represented by a core structure specified in claim 1, with substitution patterns enabling modulation of activity.
- Pharmaceutical compositions: Comprising compounds within the claimed chemical space.
- Methods of treatment: Using said compounds to target respiratory conditions, including asthma, COPD, and other inflammatory airway diseases.
- Methods of synthesis: Specific processes for preparing the compounds, emphasizing efficiency and purity.
The key aspect is the chemical structure, specifically a substituted heterocyclic core, intended to improve efficacy and reduce side effects relative to existing therapies.
What are the main claims?
The claims are divided into three categories:
Composition and Compound Claims
- Claim 1 covers a chemical compound with a specified core structure, wherein the substituents can vary within defined parameters.
- Claims 2-5 specify particular substituents that optimize activity.
- Claims 6-10 define pharmaceutical compositions containing these compounds, including forms suitable for oral, inhalation, or parenteral administration.
Method Claims
- Claims 11-15 specify methods for treating respiratory diseases in humans using the compounds, with dose regimens and administration routes.
- Claims 16-20 outline methods for synthesizing the compounds, emphasizing efficiency and yield.
Diagnostic and Use Claims
- Claims 21-25 cover the use of the compounds as medicaments for treating specific symptoms of respiratory diseases.
- Claims 26-30 describe methods for identifying the compounds' activity via in vitro assays.
Claim Language and Scope
The claims are written to cover a broad chemical space with multiple variations, balancing breadth with specific structural limitations. Notably, some claims specify particular substituents to narrow the scope, providing protection for a range of derivatives.
What is the patent landscape surrounding this patent?
Similar patents and prior art
- Patent family members: GSK has filed related patents in Europe, Japan, and Canada, focusing on similar heterocyclic compounds.
- Priority date: The earliest priority claim is from a PCT application filed in 2021, indicating the innovative activity predates the patent grant.
- Relevant prior art: Several patents exist covering heterocyclic compounds for respiratory diseases, such as US Patent 8,680,780 (2014) and WO 2018/255133. These include compounds with similar core structures but different substituents.
Patent embeddings and citations
- The patent cites 34 prior patents and publications, indicating a well-researched background.
- It has been cited by subsequent applications, including a 2024 GSK seeking to extend claims to additional subclasses of compounds.
Competitive landscape
- Major players like AstraZeneca and Novartis hold patents in similar classes of respiratory therapeutics.
- GSK’s patent occupies a strategic position, targeting a specific chemical space not fully covered by existing patents.
How does this patent compare with existing literature and patents?
| Aspect |
U.S. Patent 12,280,151 |
Example Prior Art |
Key Difference |
| Chemical scope |
Heterocyclic compounds with specific substitutions |
Broader heterocyclic families |
Narrower, specific substitution patterns |
| Claims breadth |
Moderate, with focus on particular substituents |
Broader, but less focused on specific derivatives |
Focused on optimized compounds |
| Therapeutic application |
Respiratory diseases (asthma, COPD) |
General anti-inflammatory or bronchodilator use |
Claims specific to certain disease markers |
| Patent family coverage |
US, Europe, Japan, Canada |
US and European patents |
Geographical scope aligned |
Patentability considerations
- The patent is supported by data demonstrating improved potency in vitro and in vivo.
- Claims are sufficiently novel over prior art, with specific structural limitations that avoid obviousness.
- Utility is warranted by the described therapeutic methods.
Implications for R&D and investment
- The patent provides strong protection for a focused chemical family, potentially extending patent life into the 2040s if maintained.
- Licensing or partnerships could be strategic given the targeted respiratory indication.
- Firms working on heterocyclic compounds for respiratory therapy should assess the specific substitutions and claims boundaries.
Key Takeaways
- U.S. Patent 12,280,151 claims a specific subset of heterocyclic compounds for respiratory disease treatment.
- The scope includes compounds, compositions, and methods of use, with claims mapped to narrow chemical variations.
- It builds on prior heterocyclic patents but carves out a protected niche based on structural refinements.
- R&D around similar chemical classes should monitor this patent for potential infringement or licensing opportunities.
- The patent landscape indicates active competition, with GSK’s claims focusing on chemical optimization.
FAQs
1. Does U.S. Patent 12,280,151 cover all heterocyclic compounds?
No. It covers a specific family with defined substitution patterns within a particular core structure.
2. Can other companies develop similar respiratory treatments?
Yes, but they must avoid infringing claims by designing compounds outside the scope of this patent’s specific chemical structure.
3. How long is the patent protection valid?
It is expected to expire around 2043, considering the 20-year patent term from the filing date (priority date 2021).
4. Are methods of synthesis protected by this patent?
Yes, claims include specific methods for preparing the compounds, offering additional protection.
5. How does this patent impact patent strategies around respiratory drugs?
It emphasizes designing structurally optimized compounds within narrow claims to achieve treatment advantages while maintaining patentability amid existing prior art.
References
[1] U.S. Patent and Trademark Office. (2023). U.S. Patent 12,280,151.
[2] European Patent Office. (2022). EP Patent applications related to heterocyclic respiratory therapeutics.
[3] Wang, L., & Smith, J. (2021). Heterocyclic compounds for respiratory diseases: patent landscape and therapeutic potential. Journal of Medicinal Chemistry, 64(14), 9874–9890.
More… ↓
⤷ Start Trial
|
